Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $53 per share in cash, valuing the deal at approximately $2.9 billion. The acquisition gives Neurocrine access to VYKAT XR (diazoxide choline), a first-in-class therapy approved by the FDA in 2025 for treating hyperphagia — the defining feature of Prader-Willi syndrome, a rare genetic disorder affecting roughly 10,000 patients in the U.S.

VYKAT XR generated $190 million in revenue during its first year on the market, with intellectual property protection extending through the mid-2040s. The offer represents a 34% premium over Soleno's closing price on April 2 and a 51% premium to its 30-day volume-weighted average. Soleno shares surged nearly 40% on the news.

Neurocrine CEO Kyle Gano called the deal a step toward "delivering life-changing treatments while accelerating revenue growth and portfolio diversification." The transaction is expected to close within 90 days pending regulatory approval.